# Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)

> **NCT00109122** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 180 (actual)

## Conditions studied

- Shingles

## Interventions

- **BIOLOGICAL:** zoster vaccine live (Oka/Merck)
- **BIOLOGICAL:** Comparator: placebo (unspecified)

## Key facts

- **NCT ID:** NCT00109122
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-02
- **Final completion:** 2006-07
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2017-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109122, "Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00109122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*